UBS wants to make an 'impact' with a new fund, shelling out $650M to join MPM

Max Gelman

Senior Editor

Swiss banking company UBS jumped into the deep end of biotech fundraising Wednesday, ponying up more than half a billion dollars toward new “impact” investments …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

UBS wants to make an 'impact' with a new fund, shelling out $650M to join MPM

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

How AI can address ongoing challenges in the life sciences industry

UBS wants to make an 'im­pact' with a new fund, shelling out $650M to join MPM

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

UBS wants to make an 'impact' with a new fund, shelling out $650M to join MPM